Emestedastat
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Emestedastat (proposed brand name Xanamem; developmental code name UE-2343) is a steroidogenesis inhibitor which is under development for the treatment of Alzheimer's disease, major depressive disorder, and fragile X syndrome. It is taken orally. The drug specifically acts as a centrally penetrant inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and thereby inhibits the synthesis of the glucocorticoid steroid hormone cortisol. Emestedastat was originated by the University of Edinburgh and is under development by Actinogen Medical. As of June 20261, it is in phase 2/3 clinical trials for Alzheimer's disease and phase 2 trials for major depressive disorder, whereas no recent development has been reported for fragile X syndrome. Clinical effectiveness for Alzheimer's disease has been mixed. In a phase 2 clinical trial for major depressive disorder published in July 2026, emestedastat showed no significant benefit on depressive or cognitive symptoms. In addition, it produced mild-to-moderate transaminase elevations in 10% of people, whereas this occurred in 1% in the placebo group.
Emestedastat (proposed brand name Xanamem; developmental code name UE-2343) is a steroidogenesis inhibitor which is under development for the treatment of Alzheimer's disease, major depressive disorder, and fragile X syndrome. It is taken orally. The drug specifically acts as a centrally penetrant inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and thereby inhibits the synthesis of the glucocorticoid steroid hormone cortisol. Emestedastat was originated by the University of Edinburgh and is under development by Actinogen Medical. As of June 2026, it is in phase 2/3 clinical trials for Alzheimer's disease and phase 2 trials for major depressive disorder, whereas no recent development has been reported for fragile X syndrome. Clinical effectiveness for Alzheimer's disease has been mixed. In a phase 2 clinical trial for major depressive disorder published in July 2026, emestedastat showed no significant benefit on depressive or cognitive symptoms. In addition, it produced mild-to-moderate transaminase elevations in 10% of people, whereas this occurred in 1% in the placebo group.
See also
List of investigational antidepressants
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371059574 under CC BY-SA 4.0; modifications have been made.
References
- ↩Wikipedia “Emestedastat” publication date (×1) · confidence 0.95 revision URL